数字咨询优化指南导向治疗:设计一个务实的多中心随机对照试验的设计
Jelle P Man1,2,3,4, Marcel G W Dijkgraaf5,6, M Louis Handoko2,4
1Department of Cardiology, Amsterdam UMC location AMC, Amsterdam, The Netherlands.
ESC heart failure
|December 26, 2023
概括
数字咨询可以改善心力衰竭 (HF) 患者的指南导向医学治疗 (GDMT). 该ADMINISTER试验显示,DCs可以提高GDMT优化和患者护理效率.
科学领域:
- 心脏病学 心脏病学
- 数字健康数字健康
- 医疗保健服务研究 医疗服务研究
背景情况:
- 准则导向医学治疗 (GDMT) 对于心力衰竭 (HF) 管理至关重要,但往往未得到充分利用.
- 数字咨询 (DCs) 为日益增长的高频人口提供了一个有希望的途径来提高GDMT优化效率.
研究的目的:
- 评估数字咨询 (DC) 的有效性和安全性,以优化心力衰竭 (HF) 患者的指南导向医学治疗 (GDMT).
- 评估多方面的数字咨询对GDMT处方率,优化时间,患者/临床医生的满意度和医疗保健利用率的影响.
主要方法:
- 实用性,多中心,随机对照的开放标签试验 (ADMINISTER试验) 涉及150名低射率患者.
- 干预组接受了多方面的DC:数字数据共享,电子学习患者教育和数字指南建议.
- 对照组接受了标准护理;主要结果是GDMT处方率得分.
主要成果:
- 该ADMINISTER试验将提供使用数字咨询的GDMT优化的第一个随机控制数据.
- 关键结果包括GDMT处方率,完全优化的时间,患者/临床医生满意度,医疗时间和生活质量.
结论:
- 数字咨询代表了一种新且有效的策略,用于增强心力衰竭的指导方针导向医学治疗.
- 该ADMINISTER试验的结果将为将数字健康解决方案整合到常规HF护理途径中提供信息.
相关概念视频
01:16Clinical Trials
6.7K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.7K
01:11Blinding
2.5K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.5K
01:12Hazard Ratio
129
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
129